MedTrace Logo

GW823093C For The Treatment Of Type 2 Diabetes Mellitus

NCT00370942 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 159

Last updated 2018-08-31

No results posted yet for this study

Summary

This study was designed to find dose response and as extension in treatment of GW823093C.

Conditions

  • Diabetes Mellitus, Type 2

Interventions

DRUG

GW823093C A

A=45 mg

DRUG

GW823093C B

B=30 mg

DRUG

GW823093C C

C=25 mg

Sponsors & Collaborators

Principal Investigators

  • GSK Clinical Trials · GlaxoSmithKline

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
20 Years
Max Age
74 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-04-01
Primary Completion
2006-11-01
Completion
2006-11-25

Countries

  • Japan

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00370942 on ClinicalTrials.gov